Orexo AB (STO:ORX) announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence. Global value of the opioid dependence market today is approximately […]

On the Web site of the American Society of Health System Pharmacists (ASHP), the list goes on for pages: atracurium, bumetanide, buprenorphine, clindamycin, cisatracurium, epinephrine, fentanyl, furosemide, lipid emulsion, lidocaine, metronidazole, naloxone, propofol, rocuronium, succinylcholine, sulfamethoxazole-trimethoprim, torsemide, vancomycin hydrochloride, vecuronium. They are all sterile injectable drugs that an emergency physician might use every day, and […]

About three years ago, I was attending a national conference on public health (American Public Health Association) and presenting my posters on the relationship between drug use and violence, and sexually transmitted infections and injecting drugs. As I walked the aisles I ran into a woman who runs a Florida addiction “treatment” facility. We talked […]

Conclusions.  It is difficult to determine if observed differences in abuse potential between intranasal buprenorphine and buprenorphine/naloxone are clinically relevant at the doses tested. Greater bioavailability and faster onset of pharmacodynamic effects compared to sublingual administration suggests a motivation for intranasal misuse in non‐dependent opioid abusers. However, significant naloxone absorption from intranasal buprenorphine/naloxone administration may […]